Outcomes of first-generation EGFR-TKIs against non-small-cell lung cancer harboring uncommon EGFR mutations: a post hoc analysis of the BE-POSITIVE study
S Pilotto, A Rossi, T Vavalà, A Follador, M Tiseo… - Clinical Lung Cancer, 2018 - Elsevier
Background Beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-
cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study
that reported the outcomes of first-generation epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors (TKIs) in a “real-life” Caucasian EGFR-mutated non-small-cell lung
cancer (NSCLC) population. The sharing of multi-institutional experiences represents a
crucial strategy to enrich knowledge about uncommon EGFR mutations. Therefore, we …
cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study
that reported the outcomes of first-generation epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors (TKIs) in a “real-life” Caucasian EGFR-mutated non-small-cell lung
cancer (NSCLC) population. The sharing of multi-institutional experiences represents a
crucial strategy to enrich knowledge about uncommon EGFR mutations. Therefore, we …
以上显示的是最相近的搜索结果。 查看全部搜索结果